Form 4: Olema Pharmaceuticals Director Acquires 23,000 Stock Options

Director G. Walmsley Graham acquired 23,000 stock options in Olema Pharmaceuticals, Inc. on June 14, 2024.

Summary

• On June 14, 2024, G. Walmsley Graham, a director of Olema Pharmaceuticals, Inc., acquired 23,000 stock options.
• The exercise price of these options is $12.36.
• The options vest in 12 equal monthly installments starting from June 14, 2024, and expire on June 14, 2034.
• Full vesting occurs on the date of the Issuer's next annual meeting of stockholders if the stock option is not otherwise fully vested by such date, subject to continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation practices.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into insider transactions.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry as a form of compensation and incentive.
• The vesting schedule of 12 months is fairly standard.
• Comparing the size of the grant to those of directors at comparable companies (e.g., other small to mid-cap biotech firms) would provide further context.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment, as it may signal confidence in the company's future prospects.

Key Dates